Neuren Pharmaceuticals(ASX:NEU)
Developing drug therapies forserious neurological disorders that emerge in early childhood &have no or limited treatment options
Highly successful US launchof DAYBUE™ (trofinetide) for Rett syndrome by partner Acadia
2023 net sales of US$177.2m;A$27m NEU royalties
1Q24 net sales US$75.9;A$11.6m royalties
2024 net sales guidance ofUS$370-420m; would earn NEU A$61-70m + A$77m sales milestone
Acadia advancingDAYBUE™ in Canada, Europe & Japan
NNZ-2591 in Phase 2 trialsfor four syndromes; 5x Rett market
All indications received FDAinvestigational new drug (IND) & orphan drug designation
Pitt Hopkins topline resultsexpected 2Q24, Angelman results expected 3Q24
Dec'23: PMS demonstratedsignificantly positive results, preparation underway for FDA end of Ph2 meeting
$243.1m cash as of 31 Mar'24
Market cap ~ $2.58B
Neuren Pharmaceuticals(ASX:NEU)Developing drug therapies...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.82 |
Change
-0.200(1.05%) |
Mkt cap ! $2.404B | |||
| Open | High | Low | Value | Volume |
| $18.96 | $19.06 | $18.72 | $3.641M | 193.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 259 | $18.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.83 | 890 | 29 |
View Market Depth
| Last trade - 14.39pm 12/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.82 |
Change
-0.200 ( 0.02 %) |
||||
| Open | High | Low | Volume | ||
| $18.95 | $19.02 | $18.72 | 71389 | ||
| Last updated 15.01pm 12/06/2024 ? | |||||
| NEU (ASX) Chart |